摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(2,2-dioxido-1,2-benzoxathiin-6-yl)-1-(4-methylphenyl)-1H-tetrazole | 1571901-98-8

中文名称
——
中文别名
——
英文名称
5-(2,2-dioxido-1,2-benzoxathiin-6-yl)-1-(4-methylphenyl)-1H-tetrazole
英文别名
6-[1-(4-Methylphenyl)tetrazol-5-yl]-1,2lambda6-benzoxathiine 2,2-dioxide;6-[1-(4-methylphenyl)tetrazol-5-yl]-1,2λ6-benzoxathiine 2,2-dioxide
5-(2,2-dioxido-1,2-benzoxathiin-6-yl)-1-(4-methylphenyl)-1H-tetrazole化学式
CAS
1571901-98-8
化学式
C16H12N4O3S
mdl
——
分子量
340.362
InChiKey
GVYPZNRMXFBYJN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    24
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    95.4
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

  • 作为产物:
    参考文献:
    名称:
    Synthesis of 6-tetrazolyl-substituted sulfocoumarins acting as highly potent and selective inhibitors of the tumor-associated carbonic anhydrase isoforms IX and XII
    摘要:
    A series of 6-substituted sulfocoumarins incorporating substituted-1,2,3,4-tetrazol-5-yl moieties were synthesized by reaction of 6-iodo-sulfocoumarin and the corresponding tetrazole via the CH activation reaction. The new sulfocoumarins incorporating alkyl and substituted aryl moieties at the 1-position of the tetrazole, were investigated for the inhibition of four human (h) carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, the cytosolic hCA I and II; and the transmembrane, tumor-associated hCA IX and XII. The tetrazole-substituted sulfocoumarins did not inhibit the ubiquitous, off-target cytosolic isoforms (K(I)s > 10 mu M) but showed effective inhibition against the two transmembrane CAs, with KIs ranging from 6.5 to 68.6 nM against hCA IX, and between 4.3 and 59.8 nM against hCA XII. As hCA IX and XII are validated anti-tumor targets, such prodrug, isoform-selective inhibitors as the sulfocoumarins reported here, may be useful for identifying suitable drug candidates for clinical trials. (C) 2014 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2014.01.043
点击查看最新优质反应信息